CN114980904A - 硫酸乙酰肝素(hs)低聚糖在肝缺血再灌注损伤中的影响 - Google Patents

硫酸乙酰肝素(hs)低聚糖在肝缺血再灌注损伤中的影响 Download PDF

Info

Publication number
CN114980904A
CN114980904A CN202080092829.2A CN202080092829A CN114980904A CN 114980904 A CN114980904 A CN 114980904A CN 202080092829 A CN202080092829 A CN 202080092829A CN 114980904 A CN114980904 A CN 114980904A
Authority
CN
China
Prior art keywords
alkyl
mer
aryl
compounds
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080092829.2A
Other languages
English (en)
Chinese (zh)
Inventor
凯特琳·阿诺尔德
刘健
拉法尔·波林斯基
布赖恩·库利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of CN114980904A publication Critical patent/CN114980904A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CN202080092829.2A 2019-11-13 2020-11-13 硫酸乙酰肝素(hs)低聚糖在肝缺血再灌注损伤中的影响 Pending CN114980904A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934845P 2019-11-13 2019-11-13
US62/934,845 2019-11-13
PCT/US2020/060581 WO2021097345A1 (en) 2019-11-13 2020-11-13 Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury

Publications (1)

Publication Number Publication Date
CN114980904A true CN114980904A (zh) 2022-08-30

Family

ID=75912907

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080092829.2A Pending CN114980904A (zh) 2019-11-13 2020-11-13 硫酸乙酰肝素(hs)低聚糖在肝缺血再灌注损伤中的影响

Country Status (5)

Country Link
US (1) US20220265699A1 (de)
EP (1) EP4041251A4 (de)
JP (1) JP2023501568A (de)
CN (1) CN114980904A (de)
WO (1) WO2021097345A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110446511B (zh) 2017-03-10 2024-04-02 北卡罗来纳大学查珀尔希尔分校 短效的基于肝素的抗凝血剂化合物和方法
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
JP7495061B2 (ja) 2017-11-03 2024-06-04 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 抗炎症作用を有する硫酸化オリゴ糖
US11633424B2 (en) 2018-06-20 2023-04-25 The University Of North Carolina At Chapel Hill Cell protective methods and compositions
WO2023086998A2 (en) * 2021-11-12 2023-05-19 The Board Of Regents Of The University Of Texas System Compositions and methods for rare heparan sulfate glycan-targeted cancer treatment
WO2024054682A2 (en) * 2022-09-09 2024-03-14 The University Of North Carolina At Chapel Hill Ultralow molecular weight heparin
CN116987212B (zh) * 2023-09-25 2023-12-26 山东大学 低分子量硫酸乙酰肝素及其衍生物和制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019090203A1 (en) * 2017-11-03 2019-05-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
CN110446511A (zh) * 2017-03-10 2019-11-12 北卡罗来纳大学查珀尔希尔分校 短效的基于肝素的抗凝血剂化合物和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010006635A1 (en) * 1995-09-29 2001-07-05 D. Clark Bennett Use of heparinase to decrease inflammatory responses
EP2416651A4 (de) * 2009-04-09 2014-03-26 Univ North Carolina Verfahren zur behandlung von ischämie-reperfusionsödemen
US10286047B2 (en) * 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110446511A (zh) * 2017-03-10 2019-11-12 北卡罗来纳大学查珀尔希尔分校 短效的基于肝素的抗凝血剂化合物和方法
WO2019090203A1 (en) * 2017-11-03 2019-05-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TSUNG A, SAHAI R, TANAKA H, ET AL.: "The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 201 *

Also Published As

Publication number Publication date
JP2023501568A (ja) 2023-01-18
US20220265699A1 (en) 2022-08-25
EP4041251A4 (de) 2023-11-29
WO2021097345A1 (en) 2021-05-20
EP4041251A1 (de) 2022-08-17

Similar Documents

Publication Publication Date Title
CN114980904A (zh) 硫酸乙酰肝素(hs)低聚糖在肝缺血再灌注损伤中的影响
KAKEGAWA et al. Inhibitory effects of tannins on hyaluronidase activation and on the degranulation from rat mesentery mast cells
EP2807176B1 (de) Neuartige galactosidinhibitoren von galectinen
JP4861596B2 (ja) ヒアルロン酸オリゴ糖画分およびそれを含む医薬
CN110446511B (zh) 短效的基于肝素的抗凝血剂化合物和方法
JP7495061B2 (ja) 抗炎症作用を有する硫酸化オリゴ糖
JP2015523362A (ja) ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
US20230277580A1 (en) Cell protective methods and compositions
Arnold et al. Synthetic anticoagulant heparan sulfate attenuates liver ischemia reperfusion injury
Xie et al. PICK1 confers anti-inflammatory effects in acute liver injury via suppressing M1 macrophage polarization
WO2013138951A1 (zh) 喹唑啉衍生物及其作为细胞凋亡抑制剂的用途
CN110204594B (zh) 一种蛋白激酶多肽抑制剂
BRPI0715269A2 (pt) composto, sal do composto, composiÇço farmacÊutica, mÉtodo para a fabricaÇço de uma composiÇço farmacÊutica, uso de um composto e mÉtodo para o tratamento de uma disfunÇço na coagulaÇço sanguÍnea
AU2018273411B2 (en) Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase
AU2017405304B2 (en) Heparan sulfate glycomimetic compounds and their pharmaceutical and cosmeceutical uses
Li et al. Design and synthesis of novel hederagonic acid analogs as potent anti-inflammatory compounds capable of protecting against LPS-induced acute lung injury
RU2743293C1 (ru) Применение пептида Gly-His-Lys-Val-Glu-Pro для повышения обучаемости и улучшения памяти.
US20230135239A1 (en) Drug for treating severe acute respiratory syndrome caused by coronavirus and complications thereof and use of the drug
US20220307034A1 (en) Inhibiting ape2 expression in a subject treated with a drug agent that causes increased ape2 expression
Gadi Activated protein C reverses epigenetically sustained p66Shc expression in plaque-associated macrophages in diabetes mellitus
Liu et al. Ulinastatin protects against myocardial ischemia/reperfusion injury in rats via Rho/ROCK signaling pathway
ES2903411T3 (es) AMD3100 para el tratamiento y/o la prevención de caquexia, y composición farmacéutica del mismo
Abouelella et al. Protective Effects of Melatonin and Captopril against Cardiac Oxidative Stress and Dysfunction Induced by Nicotine in Rats
WO2024086708A2 (en) Compositions and methods for preventing cardiomyopathy
Zhang et al. Research Advanced in Small Molecular Inhibitors of Human BRDT which for male contraceptives development

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination